Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Clin Exp Pharmacol Physiol ; 38(3): 164-9, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21208254

RESUMO

1. Pancuronium, cisatracurium and vecuronium are antinicotinic agents that, in contrast with d-tubocurarine and hexamethonium, exhibit anticholinesterase activity. Pancuronium-, cisatracurium- and vecuronium-induced fade results from blockade of facilitatory nicotinic receptors on motor nerves, but fade produced by such agents also depends on the presynaptic activation of inhibitory muscarinic M2 receptors by acetylcholine released from motor nerve terminals and activation of inhibitory adenosine A1 receptors by adenosine released from motor nerves and muscles. The participation of presynaptic facilitatory A2A receptors in fade caused by pancuronium, cisatracurium and vecuronium has not yet been investigated. In the present study, we determined the effects of ZM241385, an antagonist of presynaptic facilitatory A2A receptors, on fade produced by these neuromuscular relaxants in the rat phrenic nerve-diaphragm (PND) preparation. 2. The muscles were stimulated indirectly at 75±3Hz to induce a sustained tetanizing muscular contraction. The lowest concentration at which each antinicotinic agent produced fade without modifying initial tetanic tension (presynaptic action) was determined. 3. d-Tubocurarine-induced fade occurred only at 55 nmol/L, a concentration that also reduced maximal tetanic tension (post-synaptic action). At 10 nmol/L, ZM 241385 alone did not produce fade, but it did attenuate pancuronium (0.32 µmol/L)-, cisatracurium (0.32 µmol/L)- and vecuronium (0.36 µmol/L)-induced fade. 4. The fade induced by the 'pure' antinicotinic agents d-tubocurarine (55 nmol/L) and hexamethonium (413 µmol/L) was not altered by 10 nmol/L ZM 241385, indicating that presynaptic adenosine A2A receptors play a significant role in the fade produced by antinicotinic agents when such agents have anticholinesterase activity.


Assuntos
Inibidores da Colinesterase/farmacologia , Fármacos Neuromusculares/farmacologia , Junção Neuromuscular/efeitos dos fármacos , Receptor A2A de Adenosina/metabolismo , Receptores Pré-Sinápticos/metabolismo , Acetilcolina/metabolismo , Animais , Atracúrio/análogos & derivados , Atracúrio/farmacologia , Diafragma/efeitos dos fármacos , Diafragma/metabolismo , Estimulação Elétrica/métodos , Hexametônio/farmacologia , Masculino , Contração Muscular/efeitos dos fármacos , Junção Neuromuscular/metabolismo , Pancurônio/farmacologia , Nervo Frênico/efeitos dos fármacos , Nervo Frênico/metabolismo , Ratos , Ratos Wistar , Receptor Muscarínico M2/metabolismo , Receptores Nicotínicos/metabolismo , Transmissão Sináptica/efeitos dos fármacos , Triazinas/farmacologia , Triazóis/farmacologia , Tubocurarina/farmacologia , Brometo de Vecurônio/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...